Kelesitse Phiri - Concepedia

Author

Kelesitse Phiri

Harvard University ORCID

Also Known As

Kelesitse Phiri, Phiri, Kelesitse, Veena Hoffman

Publications

438

Citations

H-Index

Concepts

All Affiliations

Harvard University Cancer Research And Biostatistics Brigham and Women's Hospital New England College of Optometry Optum (United States)

About

Kelesitse Phiri is an author at Harvard University specializing in medicine, public health, and global health.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	3	3	185
2	Public Health	3	3	185
3	Epidemiology	2	2	59
4	Biostatistics	1	1	29
5	Family Medicine	1	1	30

Kelesitse Phiri

Publications

339

Citations

H-Index

Page 1

	Year	Citations
Psychosocial Factors Affecting Medication Adherence Among HIV-1 Infected Adults Receiving Combination Antiretroviral Therapy (cART) in Botswana Tan Natalie, Kelesitse Phiri, Hermann Bussmann, AIDS Research and Human Retroviruses Mental HealthSubstance Use DisordersPreventive MedicinePublic HealthHealth Services Research	2010	126
Associations of Chemokine Receptor Polymorphisms With HIV-1 Mother-to-Child Transmission in Sub-Saharan Africa: Possible Modulation of Genetic Effects by Antiretrovirals Kumud K. Singh, Michael D. Hughes, Jie Chen, JAIDS Journal of Acquired Immune Deficiency Syndromes	2008	35
A Simple Regression-based Approach to Account for Survival Bias in Birth Outcomes Research Eric J. Tchetgen Tchetgen, Kelesitse Phiri, Roger Shapiro Epidemiology Family MedicineReproductive HealthSimple Regression-based ApproachReproductive EpidemiologyHigh-risk Pregnancy	2015	30
Accuracy of ICD‐9‐CM coding to identify small for gestational age newborns Kelesitse Phiri, Sonia Hernández–Dı́az, Lawrence C. Tsen, Pharmacoepidemiology and Drug Safety Sga ClassificationNeonatologyDiagnosisPreterm Birth PredictionHigh-risk Pregnancy	2015	29
Identification of pregnancies and infants within a US commercial healthcare administrative claims database Monica L. Bertoia, Kelesitse Phiri, C. Robin Clifford, Pharmacoepidemiology and Drug Safety	2022	25
First Trimester Exposure to Antiretroviral Therapy and Risk of Birth Defects Kelesitse Phiri, Sonia Hernández–Dı́az, Kate B. Dugan, The Pediatric Infectious Disease Journal	2014	21
Development and Validation of ICD-10-CM-based Algorithms for Date of Last Menstrual Period, Pregnancy Outcomes, and Infant Outcomes Andrea K. Chomistek, Kelesitse Phiri, Michael C. Doherty, Drug Safety	2023	20
Cardiovascular Risk in Users of Mirabegron Compared with Users of Antimuscarinic Treatments for Overactive Bladder: Findings from a Non-Interventional, Multinational, Cohort Study Veena Hoffman, Jesper Hallas, Marie Linder, Drug Safety	2021	19
Antiretroviral Therapy Use During Pregnancy and the Risk of Small for Gestational Age Birth in a Medicaid Population Kelesitse Phiri, Paige L. Williams, Kate B. Dugan, The Pediatric Infectious Disease Journal	2015	14
Trends in Antiretroviral Drug Use During Pregnancy Among HIV-Infected Women on Medicaid: 2000–2007 Kelesitse Phiri, Michael A. Fischer, Helen Mogun, AIDS Patient Care and STDs	2014	10

Page 1